These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23833377)

  • 21. Efficacy And Tolerability Of Oral Iron Chelator, Deferasirox.
    Tahir A; Hussain SI; Khan HS; Khalil S; Haider SZ; Lodhi MA
    J Ayub Med Coll Abbottabad; 2021; 33(2):207-212. PubMed ID: 34137530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lactose intolerance is not the cause of gastrointestinal adverse effects in beta thalassemia patients treated with deferasirox.
    Pazgal I; Brown M; Perets TT; Niv Y; Rachmilewitz E; Stark P
    Am J Hematol; 2014 Sep; 89(9):938-9. PubMed ID: 24923845
    [No Abstract]   [Full Text] [Related]  

  • 23. Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.
    Walter PB; Macklin EA; Porter J; Evans P; Kwiatkowski JL; Neufeld EJ; Coates T; Giardina PJ; Vichinsky E; Olivieri N; Alberti D; Holland J; Harmatz P;
    Haematologica; 2008 Jun; 93(6):817-25. PubMed ID: 18469351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome.
    Polat AK; Belli AA; Karakus V; Dere Y
    An Bras Dermatol; 2017; 92(5 Suppl 1):59-61. PubMed ID: 29267448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
    Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PERFORATED DUODENAL ULCER ASSOCIATED WITH SITUS INVERSUS AND DEXTROCARDIA.
    Ibrahim M; Hussain D; Waheed S; Tahir R; Haider G; Ali N; Sarfraz SL
    J Ayub Med Coll Abbottabad; 2016; 28(1):199-200. PubMed ID: 27323596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical presentation of perforated peptic ulcer disease in a 12-year-old boy.
    Mbarushimana S; Morris-Stiff G; Thomas G
    BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24973349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perforated duodenal ulcer in a young child: an uncommon condition.
    Yadav RP; Agrawal CS; Gupta RK; Rajbansi S; Bajracharya A; Adhikary S
    JNMA J Nepal Med Assoc; 2009; 48(174):165-7. PubMed ID: 20387362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First report of drug-induced esophagitis by deferasirox.
    Yoshikawa T; Hara T; Araki H; Tsurumi H; Oyama M; Moriwaki H
    Int J Hematol; 2012 Jun; 95(6):689-91. PubMed ID: 22547195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perforated duodenal ulcer presenting with shock in a child.
    Moon D; Weeks D; Burgess B; O'Connor R
    Am J Emerg Med; 1997 Mar; 15(2):167-9. PubMed ID: 9115521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perforated peptic ulcer disease in children: association of corticosteroid therapy.
    Bickler SW; Harrison MW; Campbell JR
    J Pediatr Surg; 1993 Jun; 28(6):785-7. PubMed ID: 7687287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversible retinopathy associated with oral deferasirox therapy.
    Walia HS; Yan J
    BMJ Case Rep; 2013 Jul; 2013():. PubMed ID: 23867877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM; Cheuk DK; Ha SY; Chiang AK; Chan GC
    Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
    [No Abstract]   [Full Text] [Related]  

  • 35. Duodenal perforation in the pediatric population: two rare cases at a small community hospital.
    Hattingh G; Salas-Parra RD; Nuzhad A; Salvador J; Farkas DT
    J Surg Case Rep; 2020 Nov; 2020(11):rjaa455. PubMed ID: 33294157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
    Allegra S; De Francia S; Cusato J; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2016 Nov; 68(11):1417-1421. PubMed ID: 27672004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perforated duodenal ulcer in the third trimester of pregnancy, with survival of both the mother and neonate, in Ethiopia: a case report.
    Jidha TD; Umer KM; Beressa G; Tolossa T
    J Med Case Rep; 2022 Aug; 16(1):322. PubMed ID: 36031622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use.
    Chuang GT; Tsai IJ; Tsau YK; Lu MY
    Nephrology (Carlton); 2015 Dec; 20(12):931-5. PubMed ID: 26016559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.
    Wood JC; Kang BP; Thompson A; Giardina P; Harmatz P; Glynos T; Paley C; Coates TD
    Blood; 2010 Jul; 116(4):537-43. PubMed ID: 20421452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation.
    Bayhan T; Ünal Ş; Ünlü O; Küçüker H; Tutal AD; Karabulut E; Gümrük F
    Hematology; 2017 May; 22(4):248-251. PubMed ID: 27809710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.